PRKCB and chronic kidney disease: In renal fibrosis and chronic kidney disease, pharmacological inhibition or genetic deletion of PKCβ reverses fibrosis through the PKCβ/TGF‐β/ROS axis and restores oxidative and metabolic balance [280].